Figure 1.

OS curves in patients who received eribulin or the comparator drug according to the EU label^a. Hazard ratio is estimated based on the Cox model with stratification factors of region, HER2 status, prior capecitabine use, and study. The median OS is adjusted by study. P value is estimated based on the stratified log-rank test. ^aPatients with locally advanced or MBC who had received one or more prior chemotherapeutic regimens for advanced disease (including an anthracycline and a taxane in either the adjuvant or metastatic setting, unless patients were not suitable for these treatments). CI, confidence interval; EU, European Union; HER2, human epidermal growth factor receptor 2; MBC, metastatic breast cancer; OS, overall survival.